Laekna Therapeutics, a Chinese biotech startup that develops innovative therapeutics to treat cancer and liver diseases, announced on Wednesday the completion of a Series D funding round at $61 million to speed up the clinical trials of its drug pipeline.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
